Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost Effects on Optic Nerve Perfusion in POAG
NCT06629129Phase 1Completed
- Sponsor
- Zagazig University
- Start
- Jun 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) in primary open-angle glaucoma (POAG), sponsored by Zagazig University. Primary endpoint: Radial Peripapillary Capillary Vascular Density at 3 months. Started Jun 2024; status: completed.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
primary open-angle glaucoma (POAG)
Beyond the preview
Go deeper on NCT06629129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06629129.